SCHEDULE 13G/A: Tang Capital Reports 4.8% Passive Stake in Reviva Pharma

Tang Capital Management and affiliates reported a 4.8% passive ownership stake in Reviva Pharmaceuticals Holdings, Inc., primarily through exercisable warrants.

Summary

• Tang Capital Management, LLC, Kevin Tang, and Tang Capital Partners, LP, along with their affiliates, collectively beneficially own 3,399,975 shares of Reviva Pharmaceuticals Holdings, Inc. Common Stock.
• This ownership represents 4.8% of the Issuer's outstanding Common Stock.
• The beneficial ownership is primarily derived from warrants (the 'Warrants') that are currently exercisable.
• The percentage of class is based on a total of 71,403,588 shares of Common Stock outstanding, which includes 68,003,613 shares outstanding as of June 26, 2025, and the 3,399,975 shares issuable upon exercise of the Warrants.
• The reporting persons share both voting and dispositive power over the 3,399,975 shares.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a passive investment.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the perceived sentiment towards the company's operational or financial performance.

Positives

• The reporting persons certified that the securities were not acquired for the purpose of changing or influencing control of the issuer, indicating a passive investment stance.

Risks

• The beneficial ownership is primarily through warrants, which, if fully exercised, would lead to dilution for existing shareholders.
• The Investor Warrants held by Tang Capital Partners, LP include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 9.99% of outstanding Common Stock, with an option to increase to 19.99% with 61 days' notice.

Future Outlook

No forward-looking statements or guidance from the company are provided in this filing.

Industry Context

This filing is a routine disclosure of passive beneficial ownership by an investment firm in a publicly traded pharmaceutical company. It does not provide specific insights into broader industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant passive institutional investor's stake, which is primarily held through warrants. The 4.8% ownership is below the 5% threshold typically associated with new Schedule 13G filings, implying a potential reduction from a previous higher stake or a re-calculation.

Key Dates

Keywords

Reviva Pharmaceuticals, Tang Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Passive Investment, Biotechnology, Pharmaceuticals